Table 1.
Baseline characteristics.
| Variable | All Patients n = 1031 | MACE n = 71 | No MACE n = 960 | p-Value |
|---|---|---|---|---|
| Age | 64 (53, 72) | 71 (60, 77) | 63 (52, 72) | <0.001 |
| Sex (m) | 774/1029 (75.2%) | 47/71 (66.2%) | 727/958 (75.9%) | 0.068 |
| Cardiovascular risk factors | ||||
| Active smoking | 415/951 (43.6%) | 20/64 (31.3%) | 395/887 (44.6%) | 0.039 |
| Hypertension | 728/1027 (70.6%) | 59/71 (83.1%) | 669/956 (70%) | 0.019 |
| Hyperlipoproteinemia | 387/1024 (37.8%) | 25/71 (35.2%) | 362/953 (38%) | 0.642 |
| Diabetes | 243/1027 (23.7%) | 23/71 (32.4) | 220/956 (23%) | 0.073 |
| Body mass index (kg/m²) | 27.5 (24.9, 30.4) | 27.7 (25.5, 31.1) | 27.5 (24.9, 30.3) | 0.433 |
| Previous myocardial infarction | 72/1027 (7%) | 4/71 (5.6%) | 68/956 (7.1%) | 0.638 |
| Previous PCI | 89/1028 (8.7%) | 5/71 (7%) | 84/957 (8.8%) | 0.616 |
| Previous CABG | 19/1028 (1.8%) | 2/69 (2.9%) | 17/957 (1.8%) | 0.530 |
| ST-segment elevation | 707/1029 (68.7%) | 48/71 (67.6%) | 659/958 (68.8%) | 0.836 |
| Systolic blood pressure (mmHg) | 133 (119, 150) | 130 (110, 150) | 134 (120, 150) | 0.166 |
| Diastolic blood pressure (mmHg) | 80 (70, 89) | 77 (65, 85) | 80 (70, 89) | 0.059 |
| Heart rate (beats/min) | 76 (67, 86) | 80 (70, 96) | 76 (66, 86) | 0.001 |
| Time symptoms to balloon * (min) | 180 (110, 310) | 194 (114, 390) | 180 (109, 306) | 0.279 |
| Door-to-balloon time * (min) | 30 (22, 42) | 28 (22.5, 40) | 30 (22, 42) | 0.490 |
| Killip class on admission | <0.001 | |||
| 1 | 911/1029 (88.7%) | 46/71 (64.8%) | 865/958 (90.3%) | |
| 2 | 81/1029 (7.9%) | 16/71 (22.5%) | 65/958 (6.8%) | |
| 3 | 22/1029 (2.1%) | 5/71 (7%) | 17/958 (1.8%) | |
| 4 | 15/1029 (1.5%) | 4/71 (5.6%) | 11/958 (1.1%) | |
| Diseased vessels | 0.025 | |||
| 1 | 517/1029 (50.3%) | 27/71 (38%) | 490/958 (51.1%) | |
| 2 | 311/1029 (30.3%) | 22/71 (31%) | 289/958 (30.2%) | |
| 3 | 201/1029 (19.6%) | 22/71 (31%) | 179/958 (18.7%) | |
| Affected artery | 0.337 | |||
| left anterior descending | 425/1029 (41.4%) | 37/71 (52.1%) | 388/958 (40.5%) | |
| left circumflex | 213/1029 (20.7%) | 14/71 (19.7%) | 199/958 (20.8%) | |
| left main | 4/1029 (0.4%) | 0/71 (0%) | 4/958 (0.4%) | |
| right coronary artery | 381/1029 (37.1%) | 20/71 (28.2%) | 361/958 (37.7%) | |
| bypass graft | 6/1029 (0.6%) | 0/71 (0%) | 6/958 (0.6%) | |
| TIMI flow grade before PCI | 0.607 | |||
| 0 | 515/1029 (50.1%) | 40/71 (56.3%) | 475/958 (49.6%) | |
| 1 | 111/1029 (10.8%) | 5/71 (7%) | 106/958 (11.1%) | |
| 2 | 215/1029 (20.9%) | 13/71 (18.3%) | 202/958 (21.1%) | |
| 3 | 188/1029 (18.3%) | 13/71 (18.3%) | 175/958 (18.3%) | |
| Stent implanted | 1005/1029 (97.9%) | 69/71 (97.2%) | 936/958 (97.7%) | 0.524 |
| TIMI flow grade after PCI | 0.294 | |||
| 0 | 20/1029 (1.9%) | 1/71 (1.4%) | 19/958 (2%) | |
| 1 | 21/1029 (2.0%) | 3/71 (4.2%) | 18/958 (1.9%) | |
| 2 | 76/1029 (7.4%) | 8/71 (11.3%) | 68/958 (7.1%) | |
| 3 | 912/1029 (88.8%) | 59/71 (83.1%) | 853/958 (89%) | |
| Medication | ||||
| Glycoprotein IIb/IIIa inhibitor | 729/1028 (70.9%) | 51/71 (71.8%) | 678/957 (70.8%) | 0.860 |
| Aspirin | 1027/1029 (99.8%) | 71/71 (100%) | 956/958 (99.8%) | 0.700 |
| Clopidogrel/Prasugrel/Ticagrelor | 1028/1028 (100%) | 71/71 (100%) | 957/957 (100%) | |
| Betablocker | 983/1028 (95.6%) | 69/71 (97.2%) | 914/957 (95.5%) | 0.505 |
| ACE-inhibitor/AT-1 antagonist | 947/1028 (92.1%) | 67/71 (94.4%) | 880/957 (92%) | 0.467 |
| Aldosterone antagonist | 133/1028 (12.9%) | 23/71 (32.4%) | 110/957 (11.5%) | <0.001 |
| Statin | 990/1028 (96.3%) | 69/71 (97.2%) | 921/957 (96.2%) | 0.684 |
| Time to MRI (days) | 3 (2, 4) | 3 (2, 4) | 3 (2, 4) | 0.06 |
Data presented as n/N (%) or median (IQR). p-values were calculated for the comparison between patients with and without MACE. Numbers in bold type indicate a significant difference. * only assessed in STEMI patients (n = 795), CABG = coronary artery bypass graft; MACE = major adverse cardiac event; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction. p-values in bold indicate statistical significance < 0.05.